<DOC>
	<DOC>NCT01992549</DOC>
	<brief_summary>The purpose of the study is to collect long-term data on the inhibitor development rate of Human-cl rhFVIII in previously untreated patients with severe Hemophilia A.</brief_summary>
	<brief_title>Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>1. Patients who completed GENA05 in accordance with the study protocol 1. Severe liver or kidney disease 2. Concomitant treatment with any systemic immunosuppressive drug; 3. Other FVIII concentrate than Humancl rhFVIII was received between completion visit of GENA05 and start of GENA15 (except emergency cases).</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>